Hair loss

SiSaf’s Bio-Courier Technology Enables Clinical Trial Success for Topical Treatment of Mild to Moderate Alopecia Areata

Retrieved on: 
Lunedì, Giugno 10, 2024
Cell, DSM-IV codes, Patient, Immune system, Standard of care, Anxiety, Doctor of Philosophy, Phase, RNA, Disease, Safety, Autoimmune disease, Depression, Alopecia areata, AA, API, Dermatology, Hair loss, Psoriasis, Corneal dystrophy, Quality of life, Keloid, Cancer, Pharmaceutical industry

This demonstrates the ability of SiSaf’s technology to deliver innovative new formulations that address stability, efficacy and side effect issues.

Key Points: 
  • This demonstrates the ability of SiSaf’s technology to deliver innovative new formulations that address stability, efficacy and side effect issues.
  • However, until now the instability of the molecule and its side effects have limited its efficacy and therapeutic application.
  • Formulation with Bio-Courier technology has helped overcome these limitations and has transformed the molecule into a highly effective drug.
  • We are pleased that one of our formulations has now demonstrated positive results in a Phase II clinical trial.

CosMedical Technologies® Unveils Revitalize + Restore Microbiome Shampoo: A Revolutionary Solution for Scalp Health and Hair Growth

Retrieved on: 
Martedì, Giugno 4, 2024
Hair loss, Alopecia areata, Male, Patient, Scalp, Skin, Female, Cosmetics

Their latest product, Revitalize + Restore Microbiome Shampoo, is a testament to their dedication to innovation and excellence.

Key Points: 
  • Their latest product, Revitalize + Restore Microbiome Shampoo, is a testament to their dedication to innovation and excellence.
  • The CEO of CosMedical Technologies, Gina Stabile, stated, "Revitalize + Restore Microbiome Shampoo presents an exciting opportunity for skincare professionals to diversify their custom branded skincare portfolio.
  • “The increasing number of patients with hair thinning and other scalp issues inspired the creation of Revitalize + Restore Microbiome Shampoo."
  • For more information about CosMedical Technologies and their range of innovative skincare products, please call 800-275-3627 or write to [email protected]

HAIR SUPPLEMENTS: ARE THEY WORTH THE HYPE? ISHRS HAIR RESTORATION EXPERTS EXAMINE THE SCIENCE BEHIND KEY INGREDIENTS IN OVER-THE-COUNTER HAIR GROWTH PRODUCTS

Retrieved on: 
Venerdì, Giugno 14, 2024
Curcumin, Oxalate, Vegetable, Nutrient, Resveratrol, Patient, Vitamin D, Serum, Mineral, Iron, Vitamin, Peptide, Biotin, Minoxidil, NSF International, DHT, Quercetin, Documentation, Risk, Safety, Dihydrotestosterone, D3, Toxicity, Alopecia areata, Telogen effluvium, Health, Coffee, Tea, AA, Meal, Clutch (eggs), FDA, Miniaturization, MD, Finasteride, Hair loss, Vitamin D deficiency, Vitamin A, Zinc deficiency, Zinc, USP, Tannin, Veganism, Caffeine, Woman, OTC, Scalp, International Society, Meat, Dietary supplement

Hair restoration experts recommend establishing baseline serum levels via routine blood tests to determine whether a deficiency exists prior to supplementing it.

Key Points: 
  • Hair restoration experts recommend establishing baseline serum levels via routine blood tests to determine whether a deficiency exists prior to supplementing it.
  • Deficiency in vitamin D can cause hair loss, but there are many people with significant vitamin D deficiency who do not experience hair loss.
  • When vitamin D deficiency is determined to be the cause of hair loss, published reports show that supplementation with vitamin D3 can significantly reverse hair loss.
  • Hair transplants are the only permanent solution to hair loss, regardless of the extent of hair loss."

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Retrieved on: 
Martedì, Giugno 4, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Janus, MD, AA, Șaeș, Therapy, Hair loss, Lymphocytopenia, POC, Headache, Fatigue, Urinalysis, Patient, Safety, Hematology, Inc., Alopecia areata, Cholesterol, Vital signs, Autoimmune disease, Cytokine, Chemistry, Pharmaceutical industry

“The results from this Phase 2 proof-of-concept study of EQ101 in alopecia areata patients are very compelling,” said principal investigator, Rodney Sinclair, MD, Sinclair Dermatology, Melbourne, Victoria, Australia.

Key Points: 
  • “The results from this Phase 2 proof-of-concept study of EQ101 in alopecia areata patients are very compelling,” said principal investigator, Rodney Sinclair, MD, Sinclair Dermatology, Melbourne, Victoria, Australia.
  • The study enrolled 36 subjects at multiple clinical trial sites, with a mean baseline SALT score of 76.
  • Twenty-five subjects completed the study; eleven subjects discontinued the study early, of which only five were attributed to adverse events.
  • Table 1 outlines response data on the 25 subjects that completed 24 weeks of treatment:

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Retrieved on: 
Lunedì, Giugno 3, 2024
Standard of care, Hair loss, Inflammation, Fatigue, Calcineurin, Patient, ATC, Tremor, Safety, Kidney, Kidney transplantation, EGFR, Death, Viral, Poster, Hyperglycemia, Pharmaceutical industry

IRVINE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today presented updated data from the Company’s ongoing open-label Phase 1b trial and open-label extension study evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients. Results from the poster, titled “Biomarkers of Inflammation and eGFR in an Ongoing Phase 1B Study of an Anti-CD40L Antibody Tegoprubart, for the Prevention of Rejection in Kidney Transplant,” were presented at the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024.

Key Points: 
  • IRVINE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today presented updated data from the Company’s ongoing open-label Phase 1b trial and open-label extension study evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients.
  • “Eledon continues to build a robust set of encouraging results demonstrating the safety and efficacy of tegoprubart in kidney transplant recipients in our Phase 1b trial,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon.
  • Results demonstrated that tegoprubart is generally safe and well tolerated in patients undergoing de novo kidney transplantation.
  • Eledon is currently conducting a Phase 1b trial ( NCT05027906 ), a Phase 2 trial (BESTOW; NCT05983770 ), and a long-term safety and efficacy extension study ( NCT06126380 ) to evaluate tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant.

WOW Skin Science Launches Red Onion Black Seed Oil Products at Walmart

Retrieved on: 
Mercoledì, Maggio 29, 2024
Cosmetics, Online Retail, Retail, Department Stores, Supermarket, Specialty, Hair loss, Scalp, Skin, Smash Mouth, Castor oil

The unique properties of red onion nourish hair follicles, stimulating hair growth and collagen production for long-lasting effects.

Key Points: 
  • The unique properties of red onion nourish hair follicles, stimulating hair growth and collagen production for long-lasting effects.
  • Begin with the red onion hair oil massaged into the scalp followed by a generous amount of shampoo applied to damp hair.
  • The Red Onion Black Seed Oil products are vegan, hypoallergenic, and cruelty-free, making them suitable for all hair types.
  • Consumers can also enjoy the anti-frizz and shine benefits of the Red Onion Black Seed Oil products.

Este Medical Group Announces Premier DHI Hair Transplant Services for North American Clients in Turkey

Retrieved on: 
Mercoledì, Maggio 15, 2024
FUE, DHI, Hair loss, Follicular unit extraction, Scalp, Scar, Dentistry

Istanbul, Turkey--(Newsfile Corp. - May 15, 2024) - Este Medical Group, a leader in hair restoration and aesthetic treatments, is proud to announce the launch of its advanced Direct Hair Implantation (DHI) services tailored specifically for North American clients.

Key Points: 
  • Istanbul, Turkey--(Newsfile Corp. - May 15, 2024) - Este Medical Group, a leader in hair restoration and aesthetic treatments, is proud to announce the launch of its advanced Direct Hair Implantation (DHI) services tailored specifically for North American clients.
  • With over two decades of experience in transforming lives through aesthetic innovation, Este Medical Group's introduction of DHI hair transplant services marks a significant milestone.
  • "We are thrilled to offer our North American clients the DHI hair transplant, a procedure that epitomizes our commitment to quality and patient satisfaction."
  • For those exploring hair transplant options in Turkey, Este Medical Group also offers Turkey hair transplant services utilizing the FUE (Follicular Unit Extraction) method, renowned for its effectiveness and natural-looking results.

The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences’ Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients

Retrieved on: 
Venerdì, Maggio 10, 2024
Research, Medical Devices, Women, Clinical Trials, Health Technology, Biotechnology, Consumer, Health, Science, Oncology, Patient, Pressure, Recurrence, Risk, Breast, Nausea, National Health Service, Exact sciences, Male, Triple-negative breast cancer, Breast cancer, HR, Hair loss, NHS trust, Prince Philip Hospital, Intersex, Neoplasm, Woman, Fatigue, Menopause, NHS

NICE confirmed that breast cancer patients who are male and trans, non-binary or intersex may benefit from the test depending on their hormonal profile.

Key Points: 
  • NICE confirmed that breast cancer patients who are male and trans, non-binary or intersex may benefit from the test depending on their hormonal profile.
  • Access to genomic testing for patients with lymph node-positive breast cancer addresses the issue of overtreatment with chemotherapy, helping many patients to avoid treatment side effects such as nausea, fatigue, hair loss and potentially secondary cancer.
  • In addition, expanded reimbursement has the potential to free up resources and capacity within NHS breast cancer services.
  • The Oncotype DX Breast Recurrence Score result enables us to do this effectively by providing specific information about an individual’s response to chemotherapy.

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Retrieved on: 
Martedì, Maggio 7, 2024
Congress, University, Insulin, Glomerular filtration rate, Risk, Nephrotoxicity, JDRF, Immunosuppression, Death, Neurotoxicity, Viral, EGFR, Hair loss, Patient, Kidney transplantation, Fatigue, Hypertension, Toxicity, Quality of life, Calcineurin, Pharmaceutical industry

IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with a novel immunosuppression regimen including tegoprubart, the company’s novel anti-CD40L antibody, which is in development for the prevention of pancreatic islet cell transplant rejection in patients with type 1 diabetes. The study is being conducted by the research team at University of Chicago Medicine’s Pancreatic and Islet Transplant Program. Separately, the company reported updated data from its ongoing Phase 1b trial demonstrating tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated.

Key Points: 
  • The study is being conducted by the research team at University of Chicago Medicine’s Pancreatic and Islet Transplant Program.
  • Separately, the company reported updated data from its ongoing Phase 1b trial demonstrating tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated.
  • Eledon is supplying tegoprubart as a cornerstone component of the immunosuppressive regimen for trial participants and tegoprubart is being evaluated for the prevention of transplant rejection in the trial.
  • Eledon is currently conducting a Phase 1b trial ( NCT05027906 ), the Phase 2 BESTOW trial ( NCT05983770 ), and a Long-Term Safety and Efficacy extension study ( NCT06126380 ) to evaluate tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant.

Dr.FORHAIR's Advanced Hair Care Products Make Thoughtful Mother's Day Gift

Retrieved on: 
Mercoledì, Maggio 8, 2024
Olive, Health, Elasticity, Hair loss, Sensation, Olive Young, Gland, Scalp, Costco, Itch, Cosmetics

LOS ANGELES, May 8, 2024 /PRNewswire/ -- Dr.FORHAIR, a functional hair care brand with clinically-validated scalp-based solutions, offers effective and safe Mother's Day gifts that are bound to impress. The research-backed brand is known for its award-winning Folligen Original Shampoo, the hair loss shampoo that recently launched offline in the U.S. after its standout reception online. The key ingredient to this hair loss shampoo is the patented Folligen Complex™, a clinically-tested solution lowering sebum and dead skin cells to unlock voluminous and silky hair.

Key Points: 
  • Through meticulous testing, the advanced hair care products are verified to be silicone oil-free, sulfate-free, paraben-free, color-safe, and hypoallergenic, ensuring formulas that are gentle while also giving the gift of youthful, luscious hair for every mom.
  • The easy spray-and-go application makes it a perfect all-around gift for moms, serving as a convenient addition to the normal hair care routine.
  • For a deep cleansing feel, Folligen Sea Salt Scaler is an advanced hair care option for an at-home spa for Mother's Day.
  • With multitasking products that are also clinically proven to be effective and safe, the Folligen line offers a refreshing upgrade to thinning hair, making for a thoughtful gift.